Bleeding Disorders Therapeutics Market Size, Share and Global Trend By Product (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Anti-fibrinolytic, Fibrin Sealants), By Type (Hemophilia A, Hemophilia B, Von Willebrand Disease), By End Users (Hospitals, Ambulatory Surgical Centres, Specialty Clinics) and Regional Forecast, 2024-2032

A bleeding disorder is a term collectively used for medical conditions where the blood is unable to form clot properly. Frequent nose bleeding, heavy menstrual bleeding, excessive bruising, and extended bleeding after vaccination or surgery are some of the symptoms associated with bleeding disorders. They can be acquired or congenital. Hemophilia A & B and Von Willebrand's disease are the most common types of bleeding disorders among people. Others include vitamin K deficiency, factor II, V, VII, X, or XII deficiencies.

According to the World Federation of Hemophilia (WFH), it was estimated that the number of people with bleeding disorders increased by 6.8% from 2016 to 2017 which is likely to upsurge the demand for the effective therapies to treat the various bleeding disorders and additionally new product launches by many key players are likely to boost the growth of bleeding disorders therapeutics market during the forecast period.

In March 2019, Biotest AG received the for usage of reduced Haemoctin SDH volume by half for the treatment of hemophilia A.This reduction in the solvent volume enhanced the quality life of the patient, especially in small children suffering with hemophilia A by minimizing the duration of injection and exposing less stress on the veins of small children.

Certain factors anticipated to accelerate the growth of the bleeding disorders therapeutics market during the forecast period are the presence of potential pipeline candidates in R&D, growing prevalence of Hemophilia, and an increase in the demand for cost-effective treatment options for the treatment of various bleeding disorders.

However, increasing cost of the treatment unaffordable by low-middle income countries is likely to hamper the growth of bleeding disorders therapeutics market during the forecast period.

Key Players Covered

Some of the major companies that are present in the global Bleeding Disorders Therapeutics market are Grifols, S.A., CSL, Octapharma, Shire, Kedrion S.p.A, China Biologic Products Holdings, Inc., Bayer AG, Pfizer Inc., Novo Nordisk A/S, others.

SEGMENTATION

Among product segmentation, the recombinant coagulation factor concentrates segment is anticipated to account for the largest share of global bleeding disorders therapeutics market during the forecast period owing to the growing usage of it as the most critical form of treatment for the Hemophilia A disease.

Key Insights

• Reimbursement Scenario for Key Countries


• Recent Industry Developments Such as Partnerships, Mergers, And Acquisitions


• Pipeline Analysis


• Advancements in Bleeding Disorder Therapeutics


• Regulatory Scenario for Key Countries/Regions

Regional Analysis

Geographically, the global bleeding disorders therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are likely to dominate the bleeding disorders therapeutics the market during the forecast period owing to the increase in the prevalence bleeding disorders and growing investments in research activities by many key players in the development of novel products. In the Asia Pacific region, China and India are expected to be the fast emerging markets due to the rising awareness by government organizations about the various bleeding disorders & available treatment options and increase in the development of healthcare infrastructures.

Key Industry Developments

• In March 2019, Biotest AG received the regulatory approval from 13 European countries for its product offering for the treatment of Hemophilia A, called Haematin SDH.


• In February 2019, Novo Nordisk A/S received the U.S. FDA regulatory approval for its product offering of Esperoct (N8-GP) as a prophylactic treatment for Hemophilia A. It is an engineered formulation of factor VII developed by the company.


• In November 2017, Grifols received the regulatory approval from the U.S. FDA for its product offering of fibrin sealant, which was composed of fibrinogen and human thrombin.